Visit COVID-19 resources

[Skip to Content]


NICE guidance on Ocriplasmin

College Statement Ocriplasmin is a recombinant protease enzyme that is effective in lysing fibronectin and laminin bonds at the vitreoretinal interface thus relieving vitreoretinal traction following intravitreal injection. Pivotal phase III trials have shown its effectiveness in treating vitreomacular traction leading to European Union approval in March 2013. The Royal College of Ophthalmologists welcomes the